CR20120628A - Morfolinopirimidinas y su uso en terapia - Google Patents

Morfolinopirimidinas y su uso en terapia

Info

Publication number
CR20120628A
CR20120628A CR20120628A CR20120628A CR20120628A CR 20120628 A CR20120628 A CR 20120628A CR 20120628 A CR20120628 A CR 20120628A CR 20120628 A CR20120628 A CR 20120628A CR 20120628 A CR20120628 A CR 20120628A
Authority
CR
Costa Rica
Prior art keywords
therapy
morpholinopirimidinas
processes
formula
preparation
Prior art date
Application number
CR20120628A
Other languages
English (en)
Inventor
Kevin Michael Foote
Johannes Wilhelmus Maria Nissink
Paul Turner
Original Assignee
Astrazeneca Ab
Pfizer Ltd
Takeda San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Pfizer Ltd, Takeda San Diego Inc filed Critical Astrazeneca Ab
Publication of CR20120628A publication Critical patent/CR20120628A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos pirimidinílicos de fórmula (I), donde: R2 es (I) o sales farmacéuticamente aceptables de estos, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
CR20120628A 2010-06-11 2012-12-11 Morfolinopirimidinas y su uso en terapia CR20120628A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35371310P 2010-06-11 2010-06-11

Publications (1)

Publication Number Publication Date
CR20120628A true CR20120628A (es) 2013-03-13

Family

ID=44168987

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120628A CR20120628A (es) 2010-06-11 2012-12-11 Morfolinopirimidinas y su uso en terapia

Country Status (38)

Country Link
US (5) US8252802B2 (es)
EP (1) EP2579877B1 (es)
JP (1) JP5721821B2 (es)
KR (1) KR101820996B1 (es)
CN (1) CN103068391B (es)
AR (1) AR081859A1 (es)
AU (1) AU2011263491B2 (es)
BR (1) BR112012031561B1 (es)
CA (1) CA2800203C (es)
CL (1) CL2012003503A1 (es)
CO (1) CO6640270A2 (es)
CR (1) CR20120628A (es)
CU (1) CU24109B1 (es)
DK (1) DK2579877T3 (es)
DO (1) DOP2012000310A (es)
EA (1) EA022087B1 (es)
EC (1) ECSP12012334A (es)
ES (1) ES2514325T3 (es)
GT (1) GT201200334A (es)
HK (1) HK1182019A1 (es)
HR (1) HRP20140953T1 (es)
MX (1) MX2012014477A (es)
MY (1) MY158193A (es)
NI (1) NI201200184A (es)
NZ (1) NZ604480A (es)
PE (1) PE20130306A1 (es)
PL (1) PL2579877T3 (es)
PT (1) PT2579877E (es)
RS (1) RS53566B1 (es)
SA (1) SA111320519B1 (es)
SG (1) SG185711A1 (es)
SI (1) SI2579877T1 (es)
SM (1) SMT201400146B (es)
TW (1) TWI526208B (es)
UA (1) UA109010C2 (es)
UY (1) UY33440A (es)
WO (1) WO2011154737A1 (es)
ZA (1) ZA201300255B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
WO2018029117A1 (en) * 2016-08-10 2018-02-15 Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) New atr inhibitors for the use in cancer therapy
AR110995A1 (es) 2017-02-24 2019-05-22 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
PT3651768T (pt) 2017-07-13 2024-03-20 Univ Texas Inibidores heterocíclicos da atr cinase
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
EP3668839B1 (en) * 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
CN111655688B (zh) * 2017-09-08 2023-09-29 蓝谷制药有限责任公司 经取代的吡咯并吡啶类化合物作为atr抑制剂
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CA3084863A1 (en) 2017-12-08 2019-06-13 Bayer Aktiengesellschaft Predictive markers for atr kinase inhibitors
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
SI3753937T1 (sl) 2018-02-07 2024-03-29 Wuxi Biocity Biopharmaceutics Co., Ltd. Atr inhibitor in njegova uporaba
EP3765008B1 (en) 2018-03-16 2023-06-07 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
US20210369724A1 (en) 2018-10-16 2021-12-02 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
JP2022515114A (ja) * 2018-12-18 2022-02-17 アストラゼネカ・アクチエボラーグ 製薬方法及び中間体
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
GB201908536D0 (en) * 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
US20220281858A1 (en) * 2019-08-06 2022-09-08 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystalline form of atr inhibitor and use thereof
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
BR112022008000A2 (pt) * 2019-11-21 2022-07-12 Jiangsu Hengrui Medicine Co Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
CN112939966B (zh) * 2019-12-10 2023-03-24 武汉光谷亚太医药研究院有限公司 嘧啶衍生物、其制备及应用
TW202140474A (zh) * 2020-01-17 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2021189036A1 (en) * 2020-03-20 2021-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Taf1 inhibitors
KR20230009481A (ko) 2020-05-11 2023-01-17 아스트라제네카 아베 암 치료를 위한 atr 저해제
WO2021238999A1 (zh) * 2020-05-29 2021-12-02 深圳市瓴方生物医药科技有限公司 氟代吡咯并吡啶类化合物及其应用
CN111646985A (zh) * 2020-06-01 2020-09-11 江苏集萃分子工程研究院有限公司 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法
EP4171650A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atr inhibitor
KR20230039675A (ko) * 2020-07-13 2023-03-21 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로 사용되는 피라졸로피리미딘 화합물
US20230399302A1 (en) * 2020-10-29 2023-12-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Process for the preparation of heteroaryl-substituted sulfur(vi) compounds
TW202304457A (zh) 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
CA3214408A1 (en) 2021-03-23 2022-09-29 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022200557A1 (en) 2021-03-26 2022-09-29 Astrazeneca Ab Combination treatments for melanoma
CA3218577A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IT202100021863A1 (it) 2021-08-13 2023-02-13 Univ Degli Studi Milano Morfolino pirimidine per l’uso nella prevenzione e/o nel trattamento di stati di ipereccitabilità neuronale
WO2023039573A1 (en) * 2021-09-10 2023-03-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compounds for targeted degradation of taf1
CN116283960A (zh) 2021-12-21 2023-06-23 上海安诺达生物科技有限公司 取代的稠杂环化合物及其制备方法与应用
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer
CA3240724A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer
WO2024121753A1 (en) 2022-12-06 2024-06-13 Astrazeneca Ab Polq inhibitors

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DK0961780T3 (da) 1997-02-12 2007-08-27 Electrophoretics Ltd Proteinmarkörer for lungecancer og anvendelse deraf
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
HU228964B1 (en) 1999-02-10 2013-07-29 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing them
ES2265998T3 (es) 1999-11-05 2007-03-01 Astrazeneca Ab Derivados de quizazolina como inhibidores de vegf.
EA005996B1 (ru) 2000-02-15 2005-08-25 Сьюджен, Инк. Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
EP1335906B1 (en) 2000-11-10 2006-09-27 F. Hoffman-la Roche AG Pyrimidine derivatives and their use as neuropeptide y receptor ligands
PL377821A1 (pl) 2002-11-21 2006-02-20 Chiron Corporation 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
WO2005000404A2 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
WO2006053227A2 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
AU2006313456B2 (en) 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
DE102005024494A1 (de) 2005-05-27 2006-11-30 Bayer Healthcare Ag Verwendung von Cyanopyrimidinen
JP5054004B2 (ja) * 2005-07-01 2012-10-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としてのピリミジン置換ベンゾイミダゾール誘導体
WO2007013691A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
CA2620864A1 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP4531027B2 (ja) 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
CA2622352C (en) 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
SG151327A1 (en) 2005-09-30 2009-04-30 Vertex Pharmaceuticals Incopor Deazapurines useful as inhibitors of janus kinases
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
JPWO2007063868A1 (ja) 2005-11-29 2009-05-07 東レ株式会社 アリールメチレンウレア誘導体及びその用途
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
CA2635997A1 (en) * 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP2009525337A (ja) 2006-01-30 2009-07-09 エクセリクシス， インク． Ｊａｋ−２調節因子としての４−アリール−２−アミノ−ピリミジン類又は４−アリール−２−アミノアルキル−ピリミジン類と使用方法
EP2008210A1 (en) 2006-03-15 2008-12-31 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
JP5243696B2 (ja) 2006-03-17 2013-07-24 田辺三菱製薬株式会社 ベンゼン誘導体
US8044068B2 (en) 2006-04-04 2011-10-25 Taisho Pharmaceutical Co., Ltd Aminopyrrolidine compound
RU2008145225A (ru) 2006-04-19 2010-05-27 Новартис АГ (CH) Соединения индазола и способы ингибирования cd7
WO2007126043A1 (ja) 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
JP5534811B2 (ja) 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
WO2008023180A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP2084159A1 (en) * 2006-10-16 2009-08-05 GPC Biotech Inc. Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors
BRPI0810646A2 (pt) 2007-04-12 2014-11-04 Hoffmann La Roche " compostos farmacêuticos ".
AU2008273892A1 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2010054764A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heteroaromatische verbindungen zur verwendung als hif-inhibitoren
TW201028410A (en) * 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr

Also Published As

Publication number Publication date
AR081859A1 (es) 2012-10-24
NI201200184A (es) 2014-01-23
US9421213B2 (en) 2016-08-23
WO2011154737A1 (en) 2011-12-15
RS53566B1 (en) 2015-02-27
CN103068391B (zh) 2014-11-26
DOP2012000310A (es) 2013-02-15
US20150164908A1 (en) 2015-06-18
UA109010C2 (en) 2015-07-10
KR101820996B1 (ko) 2018-01-22
SI2579877T1 (sl) 2014-11-28
SA111320519B1 (ar) 2014-07-02
US8252802B2 (en) 2012-08-28
CU20120169A7 (es) 2014-02-28
HRP20140953T1 (hr) 2014-12-05
US9155742B2 (en) 2015-10-13
BR112012031561A2 (pt) 2016-12-06
PT2579877E (pt) 2014-10-14
EA022087B1 (ru) 2015-10-30
MX2012014477A (es) 2013-06-13
ZA201300255B (en) 2013-09-25
JP2013528204A (ja) 2013-07-08
AU2011263491B2 (en) 2014-08-21
US20140018364A1 (en) 2014-01-16
CO6640270A2 (es) 2013-03-22
US20130005725A1 (en) 2013-01-03
AU2011263491A1 (en) 2013-01-24
SMT201400146B (it) 2014-11-10
ECSP12012334A (es) 2012-12-28
TW201201803A (en) 2012-01-16
HK1182019A1 (en) 2013-11-22
KR20130087008A (ko) 2013-08-05
TWI526208B (zh) 2016-03-21
PE20130306A1 (es) 2013-04-05
PL2579877T3 (pl) 2015-01-30
CU24109B1 (es) 2015-07-30
CA2800203C (en) 2019-01-22
US8999997B2 (en) 2015-04-07
CA2800203A1 (en) 2011-12-15
US20110306613A1 (en) 2011-12-15
ES2514325T3 (es) 2014-10-28
MY158193A (en) 2016-09-15
DK2579877T3 (da) 2014-10-13
CN103068391A (zh) 2013-04-24
EP2579877B1 (en) 2014-08-13
US20160074412A1 (en) 2016-03-17
SG185711A1 (en) 2012-12-28
GT201200334A (es) 2014-12-22
EP2579877A1 (en) 2013-04-17
UY33440A (es) 2012-01-31
JP5721821B2 (ja) 2015-05-20
NZ604480A (en) 2014-11-28
US8552004B2 (en) 2013-10-08
EA201201680A1 (ru) 2013-11-29
CL2012003503A1 (es) 2013-03-08
BR112012031561B1 (pt) 2019-12-03

Similar Documents

Publication Publication Date Title
CR20120628A (es) Morfolinopirimidinas y su uso en terapia
SV2010003767A (es) Compuestos pirazolicos 436
UY32203A (es) Amino pirimidinas y su uso en terapia
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
GT201300266A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20120427A (es) Derivados de pirazol como inhibidores de jak
SV2011003970A (es) Derivados de sulfonamida
UY33078A (es) Derivados de imidazoquinolina
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
UY31639A1 (es) Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
PE20151979A1 (es) Compuestos quimicos
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
SV2010003579A (es) Derivados de pirazol como inhibidores de 5-lo
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CR20120109A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20100250A7 (es) Compuestos pirazólicos 436
UY30982A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY31289A1 (es) Nuevos derivados de la quinoliniloxipiperidina y pirrolidina, su preparacion, composiciones farmaceuticas que los contiene y sus usos en el tratamieno de enfermedades
NI201200162A (es) Inhibidores de pirazolil quinoxalina cinasa
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211